Shares Outstanding (Quarterly) Chart

Historical Shares Outstanding (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 1.17M
March 31, 2026 1.166M
December 31, 2025 0.3142M
September 30, 2025 0.314M
June 30, 2025 0.2993M
March 31, 2025 52.25M
December 31, 2024 51.39M
September 30, 2024 5.411M
June 30, 2024 5.411M
March 31, 2024 5.41M
December 31, 2023 5.41M
September 30, 2023 5.41M
June 30, 2023 5.41M
March 31, 2023 5.127M
December 31, 2022 5.127M
September 30, 2022 2.942M
June 30, 2022 2.873M
March 31, 2022 2.873M
December 31, 2021 0.0069M
September 30, 2021 0.0069M
June 30, 2021 0.006M
March 31, 2021 0.0055M
December 31, 2020 0.0002M
September 30, 2020 0.0002M
June 30, 2020 0.0002M
Date Value
March 31, 2020 0.0002M
December 31, 2019 0.0723M
September 30, 2019 0.0721M
June 30, 2019 0.0718M
March 31, 2019 0.0717M
December 31, 2018 0.0716M
September 30, 2018 0.0716M
June 30, 2018 0.0714M
March 31, 2018 0.0628M
December 31, 2017 0.0002M
September 30, 2017 0.0626M
June 30, 2017 0.0626M
March 31, 2017 0.0618M
December 31, 2016 0.0563M
September 30, 2016 0.0462M
June 30, 2016 0.0462M
March 31, 2016 0.0462M
December 31, 2015 0.0462M
September 30, 2015 0.0462M
June 30, 2015 0.046M
March 31, 2015 0.0459M
December 31, 2014 0.0459M
September 30, 2014 0.0459M
June 30, 2014 0.0456M
March 31, 2014 0.0394M

Shares Outstanding Definition

The volume of stock shares issued by the company and in the hands of the public. This number entails how much is being traded in the open market. A decreasing shares outstanding over time may be the result of company buybacks. Companies frequently make stock buybacks and retire those buybacks as treasury stock.

Read full definition.

Shares Outstanding (Quarterly) Range, Past 5 Years

View Shares Outstanding (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shares Outstanding (Quarterly) Benchmarks

View Shares Outstanding (Quarterly) Benchmarks
Start Trial
Cerenome, Inc. 7.31M
ACADIA Pharmaceuticals, Inc. 172.13M
Alnylam Pharmaceuticals, Inc. 133.88M
Anika Therapeutics, Inc. 13.38M
Savara, Inc. 205.40M